Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.530
-0.120 (-4.53%)
At close: Mar 3, 2026, 4:00 PM EST
2.530
0.00 (0.00%)
Pre-market: Mar 4, 2026, 5:45 AM EST

Allogene Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
5694525419092,1283,546
Market Cap Growth
92.32%-16.50%-40.41%-57.30%-39.98%9.82%
Enterprise Value
401.52242.78180.99486.321,7412,768
Last Close Price
2.532.133.216.2914.9225.24
PE Ratio
--1.61-1.54-2.64-11.13-9.60
PS Ratio
-20545.845698.335823.8318.65-
PB Ratio
1.791.071.061.362.303.28
P/TBV Ratio
1.740.980.981.352.192.81
P/FCF Ratio
--2.25-2.26-4.03-10.32-19.58
P/OCF Ratio
--2.26-2.28-4.12-11.51-30.81
EV/Sales Ratio
-11035.441905.163117.4315.26-
EV/EBITDA Ratio
--0.94-0.58-1.51-10.25-11.04
EV/EBIT Ratio
--0.89-0.55-1.45-9.66-10.72
EV/FCF Ratio
--1.21-0.76-2.15-8.44-15.29
Debt / Equity Ratio
0.240.200.170.140.080.05
Debt / EBITDA Ratio
-0.36-0.32-0.28-0.30-0.41-0.20
Debt / FCF Ratio
-0.48-0.41-0.37-0.42-0.34-0.28
Net Debt / Equity Ratio
-0.56-0.50-0.70-0.63-0.42-0.72
Net Debt / EBITDA Ratio
0.820.811.151.312.283.10
Net Debt / FCF Ratio
1.101.041.511.871.884.29
Asset Turnover
-0.000.000.000.100
Quick Ratio
7.928.2312.109.639.558.78
Current Ratio
8.198.5412.389.849.848.96
Return on Equity (ROE)
-16.01%-54.94%-55.51%-42.76%-18.16%-37.03%
Return on Assets (ROA)
-45.67%-45.78%-44.76%-35.84%-15.82%-26.55%
Return on Invested Capital (ROIC)
-119.91%-144.39%-160.78%-84.26%-40.48%-103.55%
Return on Capital Employed (ROCE)
-49.37%-48.83%-47.72%-37.90%-16.87%-28.41%
Earnings Yield
-37.29%-61.97%-65.11%-37.84%-8.98%-10.42%
FCF Yield
-27.96%-44.47%-44.20%-24.84%-9.69%-5.11%
Buyback Yield / Dilution
-7.87%-25.31%-17.68%-0.32%-0.56%-17.87%
Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q